Why is Morepen Labs. falling/rising?

Recent Price Movement and Market Comparison

On 24 November, Morepen Laboratories closed at ₹43.10, down by ₹0.91 or 2.07% from the previous session. This drop continues a downward trend, with the stock having fallen for eight consecutive days, resulting in an 8.57% loss over this period. The stock is trading close to its 52-week low, just 3.34% above the lowest price of ₹41.66 recorded during the past year. This proximity to the annual low signals persistent selling pressure and a lack of positive catalysts to reverse the trend.

When compared to the broader market, Morepen Laboratories has significantly underperformed. Over the past week, the stock declined by 6.77%, while the Sensex remained virtually flat with a marginal 0.06% gain. The one-month performance further emphasises this divergence, with the stock down 11.84% against the Sensex’s 0.82% rise. Year-to-date, the stock has plummeted nearly 45%, in stark contrast to the Sensex’s robust 8.65% gain. Over the last year, Morepen Laboratories has delivered a negative return of 41.80%, whereas the Sensex has appreciated by 7.31%. These figures highlight the stock’s sustained underperformance relative to the benchmark indices.

Technical Indicators and Investor Participation

Technically, Morepen Laboratories is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This pattern typically signals bearish momentum and a lack of short- to medium-term buying interest. Furthermore, investor participation appears to be waning. Delivery volume on 21 November was 7.22 lakh shares, which represents a 13.39% decline compared to the five-day average delivery volume. Reduced delivery volume suggests that fewer investors are holding shares for the long term, potentially indicating diminished confidence in the stock’s prospects.

Despite these challenges, the stock maintains sufficient liquidity, with the capacity to handle trades worth approximately ₹0.14 crore based on 2% of the five-day average traded value. However, this liquidity has not translated into price support amid the prevailing negative sentiment.

Fundamental Performance and Valuation

From a fundamental perspective, Morepen Laboratories presents a mixed picture. The company boasts a low average debt-to-equity ratio of 0.01, indicating minimal leverage and a conservative capital structure. Its return on equity (ROE) stands at 6.3%, and the price-to-book value ratio is around 2, suggesting that the stock is trading at a fair valuation relative to its peers’ historical averages.

However, these positives are overshadowed by the company’s deteriorating profitability and growth metrics. Over the past year, profits have declined by 42.6%, closely mirroring the stock’s negative return of 41.80%. The company has reported negative results for three consecutive quarters, with profit before tax excluding other income falling by 41.0% to ₹15.22 crore compared to the previous four-quarter average. Similarly, the quarterly profit after tax declined by 23.7% to ₹17.67 crore. The return on capital employed (ROCE) for the half-year is notably low at 8.16%, underscoring operational inefficiencies.

Long-term growth has also been modest, with net sales increasing at an annual rate of 11.24% and operating profit growing at 8.98% over the last five years. These growth rates are insufficient to inspire investor confidence, especially given the company’s recent earnings setbacks.

Adding to concerns, domestic mutual funds hold no stake in Morepen Laboratories. Given their capacity for thorough research and due diligence, this absence may reflect a lack of conviction in the company’s business model or valuation at current levels.

Conclusion: Reasons Behind the Decline

The decline in Morepen Laboratories’ share price as of 24 November is primarily driven by a combination of weak financial performance, sustained underperformance relative to market indices, and diminishing investor interest. The company’s recent quarterly results reveal significant profit contractions, while its long-term growth trajectory remains unimpressive. The stock’s technical positioning below all major moving averages and falling delivery volumes further exacerbate bearish sentiment.

Moreover, the absence of domestic mutual fund holdings signals a lack of institutional confidence, which often weighs heavily on stock performance. Despite a fair valuation and low leverage, these factors have not been sufficient to offset concerns about profitability and growth. Consequently, Morepen Laboratories continues to trade near its 52-week lows, reflecting the market’s cautious stance on the stock’s near-term prospects.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →